Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Subjects:

Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Subjects:

Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Subjects:

Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Subjects:

Effects of increasing amounts of gravel on escape latency and aversiveness of gravel. by Ella R. Dockendorf (21533334)

“…Over five trials, latency significantly decreased in the 20 and 40 g groups. *p < 0.05 refers to effect of trial and ****p < 0.0001 refers to effect of group. …”

Effect of sample size on reproducibility. by Jan Willem Koten (17743224)

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

Effects of increasing gravel on initial escape latency in non-injured <i>vs.</i> by Ella R. Dockendorf (21533334)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Most significant muscle activation values. by María Benito-de-Pedro (22057468)

Subjects:

Column charts of SI_8min and SI_10min in the therapy and control group at follow-up. by Felix L. Herr (21544362)

Subjects:

Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment. by Felix L. Herr (21544362)

Subjects:

iKIR score decreases protection associated with protective class II genotypes in T1D. by Laura Mora-Bitria (20477525)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects: